Peptide CMC Consulting
Peptide therapeutics have emerged as a dominant class of pharmaceuticals due to their high selectivity, target affinity, and low toxicity. However, native peptides often suffer from short half-lives, poor oral bioavailability, rapid renal clearance, and susceptibility to enzymatic degradation.To overcome these biological limitations, medicinal chemists use tailored rational design strategies.
LIPIDATION
Half-Life Extension: The lipid tail non-covalently binds to human serum albumin in the bloodstream. This creates a circulating drug reservoir, dramatically extending plasma half-life by shielding the peptide from enzymatic breakdown and reducing renal clearance.
Membrane Permeation: Fatty acid tails increase overall hydrophobicity, promoting interaction with cell membranes and improving cellular uptake or tissue retention.
Therapeutic Examples:
Liraglutide &
Semaglutide: GLP-1 receptor agonists modified with palmitic acid and a di-acid fatty chain, respectively, converting daily or hourly native peptides into once-daily or once-weekly treatments.
Insulin Detemir: A lipidated insulin analogue providing prolonged basal control.
STAPLED BACKBONE
Unmodified peptides are inherently flexible, adopting many dynamic conformations in solution. Constraining a peptide locks its structure into the "bioactive" conformation needed to bind its receptor. This locks out inactive shapes, increases binding affinity, and blocks proteolytic enzymes from accessing the peptide backbone.
MACROCYCLES
These constructs feature two or more interconnected peptide rings anchored by a central molecular core.Benefits: Combines antibody-like binding affinity with the deep tissue penetration and low cost of small molecules.Example: Bicycle Therapeutics' Bicycle Toxin Conjugates (BTCs) designed for targeted oncology delivery.
PEGYLATION
PEGylation is the covalent attachment of polyethylene glycol (PEG) polymer chains to the peptide. PEG binds water molecules, dramatically increasing the overall hydrodynamic radius of the peptide beyond the glomerular filtration threshold of the kidneys, preventing rapid urinary excretion
COMMON BOTTLENECKS IN PEPTIDE DEVELOPMENT
While the technology for synthesis of complex peptides is nominally available among a range of CDMO service providers, many do not possess the sophisticated analytical capability to ensure the correct peptide is being delivered. Additionally, synthesis route selection should be conducted with a view to scalabiltiy and robustness. Finally, changes in peptide structure introduce solubiltiy and formualtino challenges.
Our consultants can guide you through CDMO selection, peptide design options, screening, and formulation studies. Beyond the R&D stage we can support the implementation of a scale up process under the appropriate GMP standards.
